Search clinical trials for: PF-00868554 or Placebo

Total 1149 results

Pfizer

Terminated

A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers

Healthy Volunteers

United States
Pfizer

Completed

A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

Hepatitis C

Belgium, Germany, United Kingdom
Pfizer

Completed

A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

Hepatitis C

United States, Puerto Rico
Pfizer

Completed

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

HCV

United States
Pfizer

Completed

Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554

HEPATITIS C (HCV)

United States
Pfizer

Terminated

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Psoriasis

Canada, United States, Japan, Poland
Pfizer

Completed

A Single Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Withdrawn

A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

Obesity
Pfizer

Completed

A Study Of PF-05175157 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Terminated

A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects

Healthy Volunteers

Belgium
Pfizer

Completed

A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin

Healthy

Belgium
Pfizer

Terminated

A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects

Healthy

Belgium
Pfizer

Terminated

A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects

Healthy

Belgium
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers

Healthy Volunteers

United States
Pfizer

Completed

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Israel, Korea, Republic of, Russian Federation, Turkey, Czechia, Hungary, Italy, Poland, Bulgaria, Denmark, Germany, Serbia, Austria, Slovakia, Ukraine, Georgia, Romania
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

A Single Dose Study Of PF-06678552 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340

PAIN

Belgium
Pfizer

Completed

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

Dermatitis Atopic

United States
Pfizer

Completed

Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants

Healthy

Japan
Pfizer

Completed

Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

Hepatitis, Chronic | Hepatitis C Virus

United States
Pfizer
Pfizer

Recruiting

A Phase 2/3 Study in Adult and Pediatric Participants With SCD

Sickle Cell Disease

United States, Nigeria, Kenya, Lebanon
Pfizer

Terminated

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Prostatic Neoplasms

United States
Pfizer

Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Pfizer

Withdrawn

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects (A7881006)

Respiratory Tract Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma, Bronchial
Pfizer

Completed

A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865

Healthy

Netherlands
Pfizer

Completed

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis With Liver Fibrosis

Hong Kong, United States, Taiwan, Puerto Rico, China, Canada, Korea, Republic of, Bulgaria, Japan, India, Poland, Slovakia
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Pfizer

Completed

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Healthy | Chronic Rhinosinusitis With Nasal Polyps | Atopic Dermatitis

United States
Pfizer

Completed

A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects

Healthy

United States
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Canada
Pfizer

Completed

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Anorexia | Breast Cancer | Fatigue | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Cachexia | Non-small Cell Lung Cancer | Loss of Appetite

United States, Canada
Pfizer

Completed

A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Pfizer

Terminated

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

Healthy

United States
Pfizer

Completed

Study in Healthy Adults Evaluating PF-07202954

Liver Fibrosis | Non-Alcoholic Fatty Liver Disease

United States
Pfizer

Completed

A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy

Type 2 Diabetes Mellitus

Japan
Pfizer

Completed

Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Pfizer

Active, not recruiting

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Spain, Belgium, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, France, Italy, United Kingdom, Russian Federation, Israel, Switzerland
Pfizer

Completed

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

Healthy

United States
Pfizer

Completed

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults

Healthy Participants

United States
Pfizer

Completed

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Healthy | Sickle Cell Anemia

United States
Pfizer

Completed

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

Healthy

United States
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal

Cannabis Dependence

United States

3

Subscribe